{"id":4296,"date":"2026-10-29T15:05:21","date_gmt":"2026-10-29T15:05:21","guid":{"rendered":"https:\/\/xesi.net\/?p=4296"},"modified":"2026-10-29T15:05:21","modified_gmt":"2026-10-29T15:05:21","slug":"researchers-identify-genetic-key-to-aggressive-treatment-resistant-prostate-cancer","status":"publish","type":"post","link":"https:\/\/xesi.net\/?p=4296","title":{"rendered":"Researchers Identify Genetic Key to Aggressive, Treatment-Resistant Prostate Cancer"},"content":{"rendered":"<p>Researchers at the University of Michigan Rogel Cancer Center have identified a critical genetic driver that enables prostate cancer cells to transition into a more aggressive, treatment-resistant state. This discovery, published in the <em>Journal of Clinical Investigation<\/em>, sheds light on the biological mechanisms behind &quot;lineage plasticity&quot;\u2014a process that allows cancer cells to shed their dependence on traditional hormonal treatments. More importantly, the research team has identified an existing class of drugs that may offer a viable therapeutic strategy for patients battling these difficult-to-treat subtypes of the disease.<\/p>\n<p>For many men diagnosed with advanced prostate cancer, the initial standard of care involves androgen deprivation therapy. Because most prostate cancers rely on the androgen receptor to grow and spread, blocking this receptor or its signaling pathway is highly effective for a period. However, this clinical success is often temporary. Over time, many tumors develop the ability to survive and thrive even when androgen receptor signaling is effectively silenced.<\/p>\n<p>&quot;Patients whose prostate tumors lose reliance on the androgen receptor do poorly,&quot; explains senior study author Dr. Joshi J. Alumkal, the Wicha Family Professor of Oncology at the Rogel Cancer Center. &quot;Our results suggest a therapeutic approach for patients whose tumors have undergone that shift.&quot;<\/p>\n<h3>The Challenge of Lineage Plasticity<\/h3>\n<p>The process of lineage plasticity represents a significant hurdle in modern oncology. As cancer cells become resistant to androgen receptor-targeted therapies, they do not simply stop growing. Instead, they undergo a fundamental identity shift. They abandon their original &quot;glandular&quot; identity and adopt alternate cellular characteristics. This transition is not an on-off switch but rather a continuum, with cancer cells evolving into various, more resilient forms. <\/p>\n<p>Under the leadership of Dr. Zhi Duan, the research team set out to determine exactly what triggers this transition. By analyzing patient tumor biopsies, the team searched for the molecular architects behind this transformation. Their investigation led them to a gene known as PROX1, which is known to play a vital role in dictating cell identity in both healthy development and disease states.<\/p>\n<p>The team\u2019s analysis revealed a striking correlation: as prostate cancer cells began to shift toward an alternate identity, the expression of the PROX1 gene increased significantly. When the researchers examined hundreds of patient tumor samples across the spectrum of lineage plasticity, PROX1 consistently emerged as the top upregulated gene.<\/p>\n<p>The study confirmed that PROX1 serves as an early marker for this dangerous transformation. The researchers observed that tumors with low androgen receptor activity\u2014often referred to as &quot;double-negative&quot; prostate cancer\u2014as well as those that had completely abandoned androgen receptor expression, known as &quot;neuroendocrine&quot; prostate cancer, both displayed high levels of PROX1 activity. <\/p>\n<p>Further experimental data reinforced the hypothesis that PROX1 is a causal factor. In the lab, researchers observed that PROX1 expression was inversely correlated with androgen receptor expression in patient tumor datasets. Most tellingly, when the team introduced PROX1 into prostate cancer cells that were still dependent on the androgen receptor, the gene effectively turned that receptor off.<\/p>\n<p>&quot;We think PROX1 is regulating the androgen receptor,&quot; said Dr. Alumkal. &quot;It may be one explanation for why the androgen receptor gets turned off when tumors undergo lineage plasticity and transition away from the typical glandular prostate cancer identity.&quot;<\/p>\n<h3>A Potential Path to New Treatments<\/h3>\n<p>Having identified PROX1 as a primary driver of this aggressive transformation, the next phase of the research focused on whether targeting this gene could halt tumor growth. When the team used genetic methods to eliminate PROX1 expression in both double-negative and neuroendocrine prostate cancer cell lines, the results were definitive: the cancer cells ceased to grow and began to die.<\/p>\n<p>However, translating this finding into a clinical treatment presented a significant obstacle. PROX1 is a transcription factor\u2014a type of protein that acts as a switch to turn other genes on or off. Historically, transcription factors have been notoriously difficult to target with conventional small-molecule drugs because they often lack the distinct structural &quot;pockets&quot; that drugs typically bind to.<\/p>\n<p>Faced with this challenge, the team looked to the biological environment surrounding the protein. &quot;We examined the proteins that bind to PROX1,&quot; Dr. Alumkal explained. &quot;Among the top partners were histone deacetylases, or HDACs. We felt like this was guilt by association. We hypothesized that HDACs might cooperate with PROX1 and that targeting HDACs might be like targeting PROX1.&quot;<\/p>\n<p>HDACs are enzymes that play a crucial role in regulating gene expression, and their involvement in cancer progression is well-documented in the scientific literature. Because of their known role in other malignancies, several HDAC inhibitors have already received approval from the U.S. Food and Drug Administration for the treatment of other cancer types. <\/p>\n<p>The research team found that prostate cancer cells expressing PROX1 were remarkably sensitive to these HDAC inhibitors. When treated, the cancer cells showed a depletion of the PROX1 protein. As the levels of PROX1 fell, the tumor cells began to die, mirroring the effects the team had seen when they genetically silenced the gene.<\/p>\n<h3>Looking Toward the Clinic<\/h3>\n<p>The implications of this study are far-reaching. By identifying an existing, FDA-approved class of drugs that can effectively neutralize a key driver of treatment-resistant prostate cancer, the researchers have provided a clear roadmap for future clinical trials. <\/p>\n<p>&quot;Our work implicates PROX1 as an important early driver away from androgen receptor dependence,&quot; Dr. Alumkal noted. &quot;HDAC inhibitors can block PROX1 and reduce survival of aggressive prostate tumor models that have transitioned away from androgen receptor reliance. Our results suggest this class of drugs should be prioritized for clinical trials in patients who have aggressive prostate cancer subtypes, for which there are few treatment options.&quot;<\/p>\n<p>The research represents a collaborative effort involving a vast team of scientists and clinicians across multiple disciplines and institutions. The study\u2019s authors include a wide range of experts, including Mingchen Shi, Anbarasu Kumaraswamy, Dong Lin, Dhruv Khokhani, Yong Wang, Chao Zhang, Fiana Flores, Eva Rodansky, Olivia A. Swaim, William K. Storck, Hannah Beck, Radhika A. Patel, Erolcan Sayar, Brian P. Hanratty, Hui Xue, Xin Dong, Zoe R. Maylin, Rensheng Wan, David A. Quigley, Martin Sjostrom, Ya-Mei Hu, Faming Zhao, Zheng Xia, Siyuan Cheng, Xiuping Yu, Felix Y. Feng, Li Zhang, Rahul Aggarwal, Eric J. Small, Visweswaran Ravikumar, Arvind Rao, Karan Bedi, John K. Lee, Colm Morrissey, Ilsa Coleman, Peter S. Nelson, Eva Corey, Aaron Udager, Ryan Rebernick, Marcin P. Cieslik, Arul M. Chinnaiyan, Joel A. Yates, Michael C. Haffner, and Yuzhuo Wang.<\/p>\n<p>The research was made possible through extensive funding support from various national and international organizations. Primary contributors include the National Institutes of Health, the U.S. Department of Defense, the Joint Institute for Cancer Research, the Prostate Cancer Foundation, the Canadian Institutes of Health Research, the Terry Fox Research Institute, the Canadian Cancer Society, the BC Cancer Foundation, the Smith Family Scholar Award, the Sheppard Family Foundation, the Benioff Initiative for Prostate Cancer Research, the Silver Family Innovation Foundation, the National Science Foundation, and the Institute for Prostate Cancer Research.<\/p>\n<p>As the team moves forward, the focus will likely shift toward clinical validation, testing whether these HDAC inhibitors can provide the same life-extending benefits in human patients as they have demonstrated in laboratory models. For those with aggressive, treatment-resistant prostate cancer, these findings offer a renewed sense of hope, potentially turning a biological dead-end into a new avenue for life-saving therapy.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Researchers at the University of Michigan Rogel Cancer Center have identified a critical genetic driver that enables prostate cancer cells to transition into a more aggressive, treatment-resistant state. This discovery, published in the Journal of Clinical Investigation, sheds light on the biological mechanisms behind &quot;lineage plasticity&quot;\u2014a process that allows cancer cells to shed their dependence [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4295,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[650],"tags":[3611,1168,652,2242,451,156,2245,653,2244,2243,651],"class_list":["post-4296","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-and-wellness","tag-aggressive","tag-cancer","tag-fitness","tag-genetic","tag-health","tag-identify","tag-prostate","tag-researchers","tag-resistant","tag-treatment","tag-wellness"],"_links":{"self":[{"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/posts\/4296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4296"}],"version-history":[{"count":0,"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/posts\/4296\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=\/wp\/v2\/media\/4295"}],"wp:attachment":[{"href":"https:\/\/xesi.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xesi.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}